Consequently, many cancer patients with elevated CRABP2 expression, such as those with TGCT, PRAD, LUAD, UVM, LIHC, thyroid carcinoma (THCA), stomach adenocarcinoma (STAD), skin cutaneous melanoma (SKCM), brain lower grade glioma (LGG), kidney renal papillary cell carcinoma (KIRP), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), esophageal carcinoma (ESCA), colon adenocarcinoma (COAD), and breast invasive carcinoma (BRCA), may benefit from certain immune checkpoint inhibitor therapy. The gene discussed is CRABP2; the disease is cutaneous melanoma.